Home
About
Publications Trends
Recent Publications
Expert Search
Archive
the international cancer genome consortium (icgc)
Who are the participants of the ICGC?
The ICGC consists of a network of global research institutions and organizations. Some of the notable participants include the
National Cancer Institute (NCI)
in the United States,
Cancer Research UK
, the
Riken Institute
in Japan, and the
Ontario Institute for Cancer Research (OICR)
in Canada. These institutions contribute to various projects and share their findings to build a comprehensive cancer genome database.
Frequently asked queries:
Who are the participants of the ICGC?
How does the ICGC collect and analyze data?
What types of cancers are studied by the ICGC?
How is the data made accessible to researchers?
What are some key achievements of the ICGC?
What are the future directions for the ICGC?
How can researchers and institutions get involved with the ICGC?
What Are the Limitations of Immunophenotyping?
How Do These Regulations Impact Cancer Research?
What are Common Mental Health Challenges Faced by Cancer Patients?
How Do Doctors Monitor and Manage Side Effects?
What Are the Consequences of Privacy Violations for Patients?
Why is Studying Healthcare Utilization Important in Cancer Care?
What are Genetic Variants?
How Does MDR Develop?
How Do Chemical Changes Contribute to Cancer Development?
What Role Do Regulations Play in Reducing Cancer Risks?
How is CIN Diagnosed?
Why are Animal Studies Important?
Are Chloramines Safe?
Follow Us
Facebook
Linkedin
Youtube
Instagram
Top Searches
Brain Tumor
Breast cancer
cancer
Cancer Genomics
Chemotherapy
hepatocellular carcinoma
Nanotechnology
Non-Hodgkin’s Lymphoma
Partnered Content Networks
Relevant Topics
4D Segmentation
Alopecia
Atlas-based Segmentation
Automated Segmentation
B-cell malignancies
biomarkers
Brain Tumor
Brain Tumor Segmentation
Breast cancer
cancer
Cancer Genome Atlas
Cancer genomics
Cancer treatment
CAR T-cell therapy
cell adhesion
cell migration
chemotherapy
Chromatin remodeling genes
CIAbimatoprost
Combination therapy
Copy number variations
cytokine release syndrome
Deep Learning
diffuse large B-cell lymphoma
docetaxel-cyclophosphamide
Drug delivery
epirubicin-cyclophosphamide
extracellular matrix
Genetic alteration
Glioblastoma
Gold nanoparticles
Hepatocellular carcinoma
High Tumor
image-guided radiotherapy
Imaging Techniques
Immunotherapy
Integrative genomics
integrin inhibitors
Integrins
Keratinocyte
Lipid-based nanoparticles
liver cancer
Machine Learning
Magnetic Resonance Imaging
metastasis
methyltransferase
MRI
Multi-modal Imaging
Mutual exclusivity analysis
Nanoparticles
Nanotechnology
neoadjuvant radiotherapy
neurotoxicity
Next-generation sequencing
nnovative Biomarkers
Non-Hodgkin’s lymphoma
Novel Biomarkers for Brain Tumors
Novel Chemotherapy
Oncogenic transcription factors
oncological diseases
paclitaxel
Personalized medicine
Photobiomodulation therapy
Polymeric nanoparticles
portal vein tumor thrombus
Probabilistic Models
radiotherapy
refractory lymphoma
relapsed lymphoma
Silver nanoparticles
stereotactic body radiation therapy
Targeted therapy
Tolerability
transarterial chemoembolization
tumor microenvironment
tumor progression
Voltage-gated sodium channels
Subscribe to our Newsletter
Stay updated with our latest news and offers related to Cancer.
Subscribe